allergytalk

Episode 19 - Using Fractional Exhaled Nitric Oxide to Guide Step-down Treatment Decisions

For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today's topic!

Article links:

Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. 

Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 18 - Asthma severity and Difficulty Learning to Read

For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Changes in asthma severity in the first year of school and difficulty learning to read.

IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

 

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 17: Reintroduction Failure after Negative Food Challenges

For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms.

 

Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy.

 

Home self-monitoring in patients with asthma using a mobile spirometry system.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 16: Comorbid Laryngeal Dysfunction in Asthma

Show notes for Episode 16:

 

For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis.

 

Trends and Disparities in Asthma Biologic Use in the United States.

 

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 15: Prenatal Exposure to Air Pollution

For today’s episode we will be reviewing three more articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article links:

Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age

Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma

 

Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 14: Food allergy and anaphylaxis, plus success of peanut OIT

For today’s episode we will be reviewing three articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article links:

Earlier Ingestion of Peanut After Changes to Infant Feeding Guidelines: The EarlyNuts Study

 

Effect of Sleep Deprivation and Exercise on Reaction Threshold in Adults With Peanut Allergy: A Randomized Controlled Study

 

Treatment With a Platelet-Activating Factor Receptor Antagonist Improves Hemodynamics and Reduces Epinephrine Requirements, in a Lethal Rodent Model of Anaphylactic Shock

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 13, Part 2 – Delayed Drug Hypersensitivity with Dr. David Khan, MD

Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!

 

The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

Episode 13, Part 1 – Delayed Drug Hypersensitivity with Dr. David Khan, MD

Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!

 

The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

Episode 12 - Changing Biologics, Mucus Viscosity, Pemphigus and Food Allergy

For today’s episode we will be reviewing three more articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk

Article Links:

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.

Altered Viscosity of Nasal Secretions in Postnasal Drip.

Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 11: Step Up Therapy In Asthma, A Therapy For Habit Cough

For today’s episode we will be reviewing three articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk

Article links:

Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.

Unexpected and unintended cure of habit cough by proxy.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.